As research grows, patients have more choices to match their needs and goals
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
Mediterranean diet intervention in overweight and obese subjects lowers plasma cholesterol and causes changes in the gut microbiome and metabolome independently of energy intake
Aggregating data from Table 3 reveals consistent cross-barrier alterations in cytokine levels in both CSF and peripheral blood across different clinical stages (first-episode/FES, acute/ASZ, and chronic/CSZ), which hold clinical translational significance: 1)
Current GLP-1 Weight Loss Drugs Compared to GLP-1 medications like semaglutide or dual agonists like tirzepatide, Retatrutides triple-receptor activation may provide: Greater total body weight reduction Increased energy expenditure Enhanced metabolic improvements Broader hormonal targeting This positions it as one of the most promising investigational obesity treatments currently in development
Moreover, given its function as an antimicrobial agent and the repeated demonstration that copper exposure can cause growth impairment in several fish species (reviewed by Tavares-Dias, 2021), the effect of this heavy metal on the GM is highly relevant